Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 6/20 | 0.72 |
| ▸ | PRKCA | P17252 | 5/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.72 |
| ▸ | PRKCG | P05129 | 3/20 | 0.72 |
| ▸ | PRKCB | P05771 | 3/20 | 0.72 |
| ▸ | LCK | P06239 | 3/20 | 0.72 |
| ▸ | PRKCH | P24723 | 3/20 | 0.72 |
| ▸ | PRKCI | P41743 | 3/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.72 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.72 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.72 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.72 |
| ▸ | CDK2 | P24941 | 5/20 | 0.70 |
| ▸ | AURKA | O14965 | 3/20 | 0.70 |
| ▸ | CDK1 | P06493 | 3/20 | 0.70 |
| ▸ | CDK7 | P50613 | 3/20 | 0.70 |
| ▸ | CDK9 | P50750 | 3/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.70 |
| ▸ | CDK4 | P11802 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288182 | 0.91 | CDK2 (0.74) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL4164771 | 0.88 | ZAP70 (0.54) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL4170636 | 0.88 | PRKCA (0.54) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL6976605 | 0.84 | ZAP70 (1.00) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL27720404 | 0.84 | CDK2 (0.67) | PRKCAPRKCDCDK2AURKACDK1 | |
| SCHEMBL4159950 | 0.82 | CDK2 (1.00) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL4156619 | 0.82 | CDK2 (1.00) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL4170629 | 0.81 | IGF1R (0.53) | ZAP70PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL12278950 | 0.81 | CDK2 (0.51) | PRKCAPRKCDCDK2AURKACDK1 | |
| SCHEMBL6156440 | 0.81 | CDK2 (0.67) | PRKCAPRKCDCDK2AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | ZAP70 328/4885PRKCA 279/4885PRKD3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.